RLY-2608
- Generic Name
- RLY-2608
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Associated Conditions
- -
- Associated Therapies
- -
Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024
Relay Therapeutics to report interim RLY-2608 data on September 9, 2024, focusing on 600mg BID + fulvestrant in CDK4/6-experienced, PI3Kα-mutated, HR+/HER2- metastatic breast cancer patients from the ReDiscover trial. A conference call and webcast will discuss results and next steps, accessible via the company's website.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath